Parallel imaging and dobutamine stress magnetic resonance imaging in patients with atypical chest pain or equivocal ECG not suitable for stress echocardiography.

PURPOSE: The aim of this study was to evaluate the clinical utility of cardiac magnetic resonance imaging (MRI) with dobutamine stress in patients with atypical chest pain or equivocal electrocardiography (ECG) stress test, not suitable for stress echocardiography, using steady-state free-precession and parallel imaging technique. MATERIALS AND METHODS: Thirty-three patients (22 men, 11 women; mean age 62.4 years) underwent MRI with a 1.5-Tesla imager (General Electric, HD). We used an eight-channel phase-array dedicated coil. The MRI protocol included short-axis cine steady-state sequences with four-chamber parallel imaging of the left ventricle outflow tract at rest and after stress induction. Images were acquired 3 min after the intravenous injection of 5,10, 20, 30 or 40 microg/kg/min dobutamine. MRIs were analysed both at rest and at incremental dobutamine doses. Results were considered positive for coronary artery disease (CAD) if any new or worsening wall motion abnormality developed during the stress test. Twenty-two patients underwent coronary angiography; in the remaining ten, survival free from cardiovascular events over at least 9 months was considered as absence of disease. RESULTS: One patient presented severe hypertension at rest and was excluded from our study. We analysed 960 segments and observed appearance or worsening of kinesis in 29 different segments in seven patients. Seven patients were considered positive for CAD on the basis of new or worsening wall motion abnormalities during dobutamine stress, yielding an overall sensitivity of 85% and a specificity of 100% in CAD detection. CONCLUSIONS: Dobutamine stress cardiac MRI is an accurate method for assessing myocardial ischaemia in patients with CAD, and it could be useful as a noninvasive tool for excluding the disease. The increase in signal intensity and acquisition speed obtained by using steady-state free precession with parallel imaging proved useful in increasing test specificity with respect to previous similar studies.

Cervical pain and headache in patients with facial asymmetries: the effect of orthognathic surgical correction.

AIM: Facial asymmetries are often associated with cervicobrachial pain and headache. The aim of the study was to evaluate the influence of surgical orthognathic correction of facial asymmetries on the intensity of cervicobrachial pain and headache in the short and long term. METHODS: Thirty-two patients affected by maxillomandibular asymmetries associated with pain referred to occipital, cervical, dorsal and scapulohumeral areas who were undergoing orthodontic surgical correction were enrolled in the study. The pain intensity at rest and on fibromyalgia trigger points was assessed using a 0-10 Visual Analogue Scale (VAS) preoperatively (T(0)) and 5 days (T(1)), 6 months (T(2)) and 12 months (T(3)) after surgery. Functional limitation was evaluated by the same method at T(0),T(2) and T(3). RESULTS: VAS scores at rest were significantly lower at T(1), T(2) and T(3) compared to T0 in every area to which pain was referred. After 12 months (T(3)), pain at rest was completely absent in 23 patients (71.8%) in the occipital region, in 23 patients (71.8%) in the cervical area, in 22 patients (68.7%) in the dorsal area, and in 28 patients (87.5%) in the scapulohumeral area. In the other patients, the pain scores in all areas were < 1 (0.77, 0.83, 0.95, 0.5 in the occipital, cervical, dorsal, and scapulohumeral areas respectively). The VAS at neck fibromyalgia points were significantly reduced at T(1), T(2), T(3) and functional limitation was improved at T(3) and T(4) (P=0.00). CONCLUSION: This study appears to demonstrate the utility of orthognathic surgery when facial asymmetry is associated with cranial-cervicobrachial pain syndrome, presumably through a new musculoskeletal rearrangement of stomatognathic apparatus. Indeed, the surgical correction has resulted in morphological, functional and symptomatic effects.

Impairment of plasma nitric oxide availability in senescent healthy individuals: apparent involvement of extracellular superoxide dismutase activity.

To verify the potential involvement of the age-dependent modifications of EC-SOD activity in the impairment of plasma NO availability with advancing age, 40 healthy men divided into 4 age groups for the purpose of comparison (young: 27.4 +/- 1.5 years; middle: 50.8 +/- 2.2, years; old: 70.0 +/- 1.8 years; very old: 86.1 +/- 1.1 years) were enrolled in this study. Plasma samples were used for measurements of the stable end-product nitrite/nitrate (NOx), as an expression of NO availability, EC-SOD activity, thiobarbituric acid reactive substances (TBARS) as a marker of lipid peroxidation, low density lipoprotein (LDL) copper-mediated oxidation in vitro and total antioxidant capacity (TEAC). Our results indicated a significant age-related progressive decrease of plasma NOx content and EC-SOD activity and their values were positively correlated (r = 0.713, p < 0.001). Increased TBARS amount together with reduced lag time for in vitro oxidation of LDL and decreased content of TEAC were observed with advancing age. Finally, EC-SOD values were negatively correlated with plasma TBARS values (r = -0.855, p < 0.001). Findings of the present study suggest that the decrease of antioxidant defence strategies play a primary role by compromising NO availability in normally aged individuals, particularly through a progressive decrease of EC-SOD activity.

[Edematogenic syndrome in diabetics treated with insulin: a little-known complication]. / Sindrome edemigena nei diabetici trattati con insulina: una complicanza poco conosciuta.

Two cases of insulin oedema similar to that of nephrotic syndrome were described. It appeared in two diabetic patients after the beginning of insulin therapy, when glycemia was normalized, as described by other Authors, with a spontaneous tendency to decrease. Pleural and pericardial effusion were also associated. The possible pathogenesis of insulin oedema in the two cases was discussed.

[Nitrendipine, a new calcium antagonist, in the therapy of arterial hypertension]. / La nitrendipina, un nuovo calcio-antagonista, nella terapia dell'ipertensione arteriosa.

Bay e 5009 (nitrendipine) is a new calcium-antagonist that acts mainly on blood vessel smooth muscles. The effects of this drug on hypertensive patients of both sexes was investigated. Nine patients were treated for 42 days at a fixed dosage of 1 tablet/day. A highly significant fall in arterial pressure was obtained (p less than 0.001). Seven patients took 20 mg/day of nitrendipine for 14 days and a significant reduction in A.P. was obtained (p less than 0.001): for the next four weeks, the dosage was increased to 20 mg twice a day when a further decrease in systolic and diastolic A.P. was obtained without the occurrence of side effects. A further five patients were treated for 14 day (20 mg/day). These showed a fall in blood pressure levels (p less than 0.001) but suffered from slight oedema which made it necessary to suspend the treatment. An increase in heart rate was noted in all patients (p less than 0.001). This was due to reflex adrenergic activation. Nitrendipine therefore proved effective as an antihypertensive drug even at a daily dose of only 20 mg.